Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
3.050
-0.115 (-3.63%)
Jun 27, 2025, 4:00 PM - Market closed
Inventiva Revenue
In the year 2024, Inventiva had annual revenue of 14.09M EUR, down -38.24%. Inventiva had revenue of 11.36M in the half year ending December 31, 2024, a decrease of -26.34%.
Revenue (ttm)
14.09M EUR
Revenue Growth
-38.24%
P/S Ratio
31.60
Revenue / Employee
119,441 EUR
Employees
118
Market Cap
461.02M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IVA News
- 4 weeks ago - Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference - GlobeNewsWire
- 5 weeks ago - Inventiva reports 2025 First Quarter Financial Information¹ - GlobeNewsWire
- 5 weeks ago - Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - GlobeNewsWire
- 7 weeks ago - Inventiva secures the €116 million second tranche of its structured financing of up to €348 million - GlobeNewsWire
- 2 months ago - Combined General Meeting of May 22, 2025 - Availability of the preparatory documents - GlobeNewsWire
- 2 months ago - Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor - GlobeNewsWire
- 2 months ago - Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F - GlobeNewsWire
- 3 months ago - Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis - GlobeNewsWire